Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

SanReno Therapeutics

    • Home
    • SanReno Therapeutics
Company Deals

Novartis to Fully Acquire SanReno Therapeutics to Expand Kidney Drug Portfolio in China

Fineline Cube Jan 8, 2024

Novartis (NYSE: NVS), a Swiss pharmaceutical giant, has announced plans to acquire the remaining shares...

Company Deals

SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services

Fineline Cube Jul 28, 2023

Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...

Company Drug

SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301

Fineline Cube May 4, 2023

SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion...

Recent updates

  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
  • Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance
  • Zelgen’s ZGGS18 & ZG005 Cleared by NMPA for Advanced Solid Tumor Studies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Company Drug

Gan & Lee’s Insulin Glargine Wins Ethiopia Approval, Challenging Sanofi’s Dominance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.